An in vitro model to optimize dose scheduling of multimodal radioimmunotherapy and chemotherapy: Effects of p53 expression

International Journal of Cancer

Volumn 108, Issue 2, 2004, Pages 293-300

  Blumenthal, Rosalyn D ^a   Leone, Evelyn ^a   Goldenberg, David M ^a   Rodriguez, Marisol ^a   Modrak, David ^a  

^a GARDEN STATE CANCER CENTER   (United States)

Author keywords

Chemotherapy; Ovarian cancer; p53 expression; Radioimmunotherapy

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CARBOPLATIN; DOXORUBICIN; IMMUNOGLOBULIN G; PACLITAXEL; PROTEIN P53; TOPOTECAN; YTTRIUM;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELL CYCLE; CELL STRAIN; CELL STRAIN SKOV 3; CHEMOSENSITIVITY; COLORIMETRY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOSE RESPONSE; DRUG DOSE REGIMEN; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPOTHESIS; IC 50; IN VITRO STUDY; MULTIMODALITY CANCER THERAPY; NULL CELL; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOIMMUNOTHERAPY; RADIOSENSITIVITY; SUPPRESSOR GENE;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CELL DIVISION; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; DRUG ANTAGONISM; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; GENE THERAPY; HUMANS; MUTATION; OVARIAN NEOPLASMS; PACLITAXEL; RADIOIMMUNOTHERAPY; TETRAZOLIUM SALTS; THIAZOLES; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; YTTRIUM RADIOISOTOPES;

EID: 0346752001     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11534     Document Type: Article

References (58)

1. Remmenga S, Colcher D, Gansow O, Pippen C, Raubitschek A. Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monocloncal antibody therapy of a human tumor xenograft. Gynecol Oncol 1994;55:115-22.
2. 131I-labeled monoclonal antibody A33) with chemotherapy (fluorouracil). Cancer Res 1997;57:2181-6.
3. 131I-labeled monoclonal antibody 323/A3 in experimental human ovarian cancer. Int J Radiat Oncol Biol Phys 1997;38:419-28.
4. Roffler S, Chan J, Yeh M. Potentiation of radioimmunotherapy by inhibition of topoisomerase I. Cancer Res 1994;54:1276-85.
5. Behr TM, Wulst E, Radetsky S, Blumenthal R, Dunn R, Gratz S, Rave-Frank M, Schmidberger H, Raue F, Becker W. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeld antibodies in a radioresistant tumor type. Cancer Res 1997;57:5309-19.
6. Desrues B, Lena H, Brichory F, Ramee MP, Toujas L, Deiaval P, Toujas L, Dazord L. Monoclonal antibody Po66 uptake by human lung tumours implanted in nude mice: effect of co-administration with doxorubicin. Br J Cancer 1995;72:1076-82.
7. Denardo SJ, Kukis D, Kroger L, O'Donnell R, Lamborn K, Miers L, DeNardo DG, Meares CF, DeNardo GL. Synergy of taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci USA 1997;94:4000-04.
8. Katso RM, Manek S, O'Byrne K, Playford MP, Le Meuth V, Ganesan TS. Molecular approaches to diagnosis and management of ovarian cancer. Cancer Metastasis Rev 1997;16:81-107.
9. Hollstein M, Shomer B, Greenblatt M, Soussi T, Hovig E, Montesano R, Harris CC. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res 1996;24:141-6.
10. Renninson J, Baker BW, McGown AT, Murphy D, Norton JD, Fox BW, Crowther D. Immunohistochemical detection of mutant p53 protein in epithelial ovarian cancer using polyclonal antibody CMI: correlation with histopathology and clinical features. Br J Cancer 1994;69:609-12.
11. Hollstein M, Soussi T, Thomas G, von Brevern MC, Bartsch. P53 gene alterations in human tumors: perspectives for cancer control. Recent Results Cancer Res 1997;143:369-89.
12. Gallardo D, Drazan K, McBride W. Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity. Cancer Res 1996;56:4891-3.
13. Koechli O, Schaer G, Seifert B. Mutant p53 protein associated with chemosensitivity in breast cancer specimens. Lancet 1994;344:1647-8.
14. Lowe S, Bodis S, McClatchey A. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807-10.
15. Wahl A, Donaldson K, Fairchild C. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nat Med 1996;2:72-9.
16. Fan S, Smith M, Rivet D. Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxyfilline. Cancer Res 1995;55:1649-55.
17. Hamada M, Fujiwara T, Hizuta A, Gochi A, Naomoto Y, Takakura N, Takahashi K, Roth JA, Tanaka N, Orita K. The p53 gene is apotent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. J Cancer Res Clin Oncol 1996;122:360-5.
18. Havrilesky L, Elbendary A, Hurteau J, Whitaker R, Rodriguez G, Berchuk A. Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 1995;85:1006-10.
19. Greenblatt M, Bennett W, Hollstein M, Harris C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994;54:4855-78.
20. Pocard M, Chevillard S, Villaudy J, Poupon M, Dutrillaux B, Remvikos Y. Different p53 mutations produce distinct effets on the ability of colon carcinoma cells to become blocked at the G1/S boundary after irradiation. Oncogene 1996;12:975-882.
21. McIlwrath AJ, Vasey PA, Ross GM, Brown R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res 1994;54:3718-22.
22. Wang TH, Wang HS. p53, apoptosis and human cancers. J Formos Med Assoc 1996;95:509-22.
23. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R. Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol 1996;50:1536-40.
24. Debernardis D, Sire EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 1997;57:870-4.
25. Lee JM, Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev 1995;14:149-61.
26. Kawashima K, Mihara K, Usuki H, Shimizu N, Namba M. Transfected mutant p53 gene increases X-ray-induced cell killing and mutation in human fibroblasts immortalized with 4-nitroquinoline 1-oxide but does not induce neoplastic transformation of the cells. Int J Cancer 1995;61:76-9.
27. Mueller H, Eppenberger U. The dual role of mutant p53 protein in chemosensitivity of human cancers. Anticancer Res 1996;16:3845-8.
28. O'Conner P, Jackman J, Jondle D, Bhatia K, Magrath I, Kohn K. Role of th p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt's lymphoma cell lines. Cancer Res 1993;53:4776-80.
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity. J Immunol Methods 1983;65:55-63.
30. Kaser O, Castanno Y, Almendral A. Cancer of the endometrium stage I-standardized or individualized treatment? Eur J Obstet Gynecol Reprod Biol 1984;18:329-34.
31. Breidenbach M, Rein D, Mallmann P, Kurbacher C. Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment. Anticancer Drugs 2002;13:173-6.
32. McLeod H. Individualized cancer therapy: molecular approaches to the prediction of tumor response. Expert Rev Anticancer Ther 2002;2:113-9.
33. Kandioler-Eckersberger D, Kappel S, Mittlbock M, Dekan G, Ludwig C, Janschek E, Pirker R, Wolner E, Eckersberger F. The TP53 genotype but not immunohistochemical result is predictive of response to cisplatin-basd neoadjuvant thrapy in Stage III non-small cell lung cancer. J Thorac Cardiovasc Surg 1999;117:744-50.
34. Yu D, Liu B, Tan M, Li J, Wang SS, Hung MC. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms. Oncogene 1996;13:1359-65.
35. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save-Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R, Reed R. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group [see comments]. J Clin Oncol 1992;10:1049-56.
36. Vescio R, Conners K, Youngkin T, Bordin G, Robb J, Umbreit J, Hoffman RM. Cancer biology for individualized therapy: correlation of growth fraction index in native-state histoculture with tumro grade and stage. Proc Natl Acad Sci USA 1990;87:691-5.
37. Germann UA. P-glycoprotein-A mediator of multidrug resisatnce in tumor cells. Eur J Cancer 1996;32A:927-44.
38. Loe D, Deeley R, Cole S. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996;32A:945-57.
39. Weinberg M, Rauth A. 5-Fluorouracil and fractionated doses of radiation: studies with a murine squamouse cell carcinoma. Int J Radiat Oncol Biol Phys 1987;13:1691-9.
40. Byfield J, Barone R, Seagren S, Frankel S, Quinol L. Biweekly infused 5-fluorouracil and x-rays in advanced gastro-intestinal cancer. Proc Am Soc Clin Oncol 1978;18:322-4.
41. Hadler S, Negrini M, Monne M, Sabbionni S, Croce C. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res 1994;54:2095-7.
42. Mason K, Hunter N, Milas M, Abbruzzese J, Milas L. Docetaxel enhances radioresponse in vivo. Clin Cancer Res 1997;2:2431-8.
43. Anderson T, Borresen A. Alterations in the TP53 gene as a potential prognostic marker in breast carcinomas. Diagn Mol Pathol 1995;4:203-11.
44. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 1996;88:1442-55.
45. Rebischung C, Gerard J, Gayet J, Thomas G, Hamelin R, Laurent-Puig P. Prognostic value of P53 mutations in rectal carcinoma. Int J Cancer 2002;100:131-5.
46. Kielb S, Shah N, Rubin M, Sanda M. Functional p53 mutation as a molecular determinant of paclitaxel and gemcitabine suscebtibility in human bladder cancer. J Urol 2001;166:482-7.
47. Mazel S, Burtrum D, Petrie HT. Regulation of cell division cycle progression by bcl-2 expression: a potential mechanism for inhibition of programmed cell death. J Exp Med 1996;183:2219-26.
48. Tseng M, Safa A. In vitro drug screening and individualized treatment planning for cancer patients. Cancer Detect Prev 1983;6:371-9.
49. Shimizu E, Saijo N, Kanzawa F, Hoshi A, Eguchi K, Shinkai T. Correlation between drug sensitivity determined by clonogenic cell assay and clinical effect of chemotherapy in patients with primary lung cancer. Gann 1990;75:1030-35.
50. Yang S. Correlation of in vitro chemosensitivity and clinical responses to anticancer drugs in primary adenocarcinoma of the lung. J Formos Med Assoc 1990;89:214-9.
51. Bristow R, Hill R. Comparison between in vitro radiosensitivity and in vivo radioresponse in murn tumor cell lines. II: in vivo radioresponse following fractionated treatment and in vitro/in vivo correlations. Int J Radiat Oncol Biol Phys 1990;18:331-45.
52. Tonkin K, Kelland L, Steel G. A comparison of the in vivo and in vitro radiation response of three human cervix carcinomas. Radiother Oncol 1989;16:55-63.
53. Waldman T, Zhang Y, Dillehay L, Yu J, Kinzler K, Vogelstein B, Williams J. Cell-cycle arrest versus cell death in cancer therapy. Nat Med 1997;3:1034-6.
54. Wouters B, Giaccia A, Denko N, Brown J. Loss of p21Waf1/Cip1 sensitizes tumors to radiation by an apoptosis-independent mechanism. Cancer Res 1997;57:4703-6.
55. King DJ, Turner A, Farnsworth AP, Adair JR, Owens RJ, Pedley RB, Baldock D, Proudfoot KA, Lawson AD, Beeley NR. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res 1994;54:6176-85.
56. Hu S, Shively L, Raubitschek A, Sherman M, Williams LE, Wong JY, Shively JE, Wu AM. Minibody: a novel engineered anticarcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055-61.
57. Behr T, Memtsoudis S, Sharkey R, Blumenthal R, Dunn R, Gratz S, Wieland E, Nebendahl K, Schmidberger H, Goldenberg DM, Becker W. Experimental studies on the role of antibody fragments in cancer radioimmunotherapy: influence of radiations dose and dose rate on toxicity and anti-tumor efficacy. Int J Cancer 1998;77:787-95.
58. Behr T, Blumenthal R, Memtsoudis S, Shakey R, Gratz S, Becker W, Goldenberg DM. Cure of metastatic human colonic cancer in mice with radiolabeled monoclonal antibody fragments. Clin Cancer Res 2000;6:4900-7.